A greater proportion of patients with an adverse outcome had thrombophilia, particularly antiphospholipid antibodies, Factor V Leiden mutation, prothrombin 20210A mutation, and antithrombin deficiency. This evidence concerns the gene F5 and Rare hereditary thrombophilia.